Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
| Autor: | Kudrow, David1 (AUTHOR) dbkudrow@gmail.com, Cady, Roger K.2 (AUTHOR), Allan, Brent3 (AUTHOR), Pederson, Susan M.2 (AUTHOR), Hirman, Joe4 (AUTHOR), Mehta, Lahar R.2 (AUTHOR), Schaeffler, Barbara A.2 (AUTHOR) |
|---|---|
| Zdroj: | BMC Neurology. 3/19/2021, Vol. 21 Issue 1, p1-12. 12p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|